FALLS CHURCH, Va., Jan. 27 /PRNewswire/ -- FDAnews announced today its
newest publication, Pharmaceutical Corporate Compliance Report, the only
resource that provides insight into the full range of compliance risks.
"Pharmaceutical manufacturers are under attack for more than just sales
and marketing practices," says Cynthia Carter, president of FDAnews. "From
drug pricing to patient privacy, from corporate accounting to research subject
protection, more and more drug companies are facing costly and embarrassing
litigation for what has been standard business practice."
The pharmaceutical industry is coming under increased scrutiny on a host
of non-FDA regulatory issues including: FTC's pledge to step up drug company
antitrust investigations; the Accreditation Council for Continuing Education's
restrictive new CME standards; state AG enforcement initiatives; the Sarbanes-
Oxley; HIPAA privacy and Qui Tam actions.
Published biweekly, each issue of Pharmaceutical Corporate Compliance
Report goes beyond the news to answer critical compliance questions drug
companies are asking, and provides guidelines for developing, monitoring and
managing effective compliance programs. Benefit from Pharmaceutical Corporate
Compliance Report's staff of regulatory and legislative reporters, as well as
the insight of compliance experts including industry compliance and ethics
officers, attorneys, consultants and government officials who specialize in
the issues you're facing today ... and will face tomorrow.
For a limited time, FDAnews is offering Pharmaceutical Corporate
Compliance Report at a special pre-publication rate of $697, $100 off the
regular $797 subscription rate. For subscription information, call toll-free
(888) 838-5578, +1 (703) 538-7600 or visit http://www.fdanews.com/wbi/pccr/.
* Premiere issue April 2003
Pharmaceutical Corporate Compliance Report is published by FDAnews,
publishers of Drug Industry Daily, Washington Drug Letter, Part 11 Compliance
Report, Generic Line, Devices & Diagnostics Letter and many other information
services to help pharmaceutical, biotech and medical device executives meet
legal, regulatory and business challenges.